Mason Lankes

Mason Lankes
Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment

IMNN

Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment

Imunon, a pioneering biotechnology company, made history with its fourth quarter and full year 2025 financial results, showcasing a truly transformational year in the fight against ovarian cancer. The company's proprietary IL-12 immunotherapy, IMNN-001, has demonstrated unprecedented potential to redefine frontline treatment for women with newly diagnosed advanced

By Mason Lankes
PDS Biotechnology Delivers Strong Q4 2025 Results, Advancing Clinical Programs with Promising Treatments for HPV-16 Positive Head and Neck Cancer and Metastatic Castration-Resistant Prostate Cancer

PDSB

PDS Biotechnology Delivers Strong Q4 2025 Results, Advancing Clinical Programs with Promising Treatments for HPV-16 Positive Head and Neck Cancer and Metastatic Castration-Resistant Prostate Cancer

PDS Biotechnology Corporation has reported a successful fourth quarter of 2025, marked by significant progress across its clinical programs. The company's management team, comprising Dr. Frank Bedu-Addo (Chief Executive Officer), Dr. Kirk Shepherd (Chief Medical Officer), and Lars Boesgaard (Chief Financial Officer), provided an update on the company&

By Mason Lankes